Analyst firms · Monness, Crespi, Hardt · CRI
Monness, Crespi, Hardt CRI price target and rating history
Carter's Inc. (CRI) · Consumer Discretionary
Monness, Crespi, Hardt rates Carter's Inc. (CRI) Buy with a $50 price target, as of its latest action on May 7, 2026. It has published 3 rating actions on CRI since February 2024, including 1 upgrade and 1 downgrade. Across 5 firms with a CRI price target in the last 12 months, the median target is $42. Monness, Crespi, Hardt's $50 is 19% above that.
- Current rating
- Buy
- Price target
- $50
- Median target, all firms
- $42
- Actions on CRI
- 3
Monness, Crespi, Hardt price target on CRI
Every Monness, Crespi, Hardt rating on CRI
- May 7, 2026
- Mar 2, 2026
- Feb 26, 2024
How other firms rate CRI
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BMO Capital Markets | Outperform | $40 | Sep 9, 2026 |
| Wells Fargo | Equal Weight | $42 | Jun 17, 2026 |
| Monness, Crespi, Hardt | Buy | $50 | May 7, 2026 |
| Goldman Sachs | Buy | $38 | Apr 9, 2026 |
| Needham | Hold | Mar 26, 2026 | |
| Citigroup | Buy | $50 | Jan 21, 2026 |
Questions about Monness, Crespi, Hardt and CRI
- What is Monness, Crespi, Hardt's price target for CRI?
- Monness, Crespi, Hardt's latest stated price target for Carter's Inc. (CRI) is $50, from its action on May 7, 2026.
- What is Monness, Crespi, Hardt's rating on CRI?
- Monness, Crespi, Hardt rates CRI Buy, a bullish rating, as of May 7, 2026.
- When did Monness, Crespi, Hardt last change its view on CRI?
- On May 7, 2026, Monness, Crespi, Hardt raises its price target to $50 from $45, keeps Buy.
- How does Monness, Crespi, Hardt's CRI target compare with other analysts?
- Across 5 firms with a CRI price target in the last 12 months, the median target is $42. Monness, Crespi, Hardt's $50 is 19% above that.
More CRI rating histories
All Monness, Crespi, Hardt ratingsCRI news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.